---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-007620"
form_type: "8-K"
ticker: "PAYS"
cik: "0001496443"
company_name: "Paysign, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:18:19.078623+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Paysign Q3 revenue up 23% to $15.26M; pharma affordability revenue surges 219%

## Summary
- Total revenues $15.26M (+23% YoY); net income $1.44M ($0.03 diluted EPS) vs $1.10M ($0.02) prior year.
- Pharma patient affordability revenue surged 219.1% YoY, now 21.5% of total revenue; 66 active programs at quarter end.
- Adjusted EBITDA $2.83M (+20.6% YoY); FY2024 guidance reaffirmed: rev $56.5-58.5M, adj. EBITDA $9-10M.
- Plasma revenue up 3.4% YoY from 478 centers; average monthly revenue per center $7,991, down slightly from $8,041.
- Unrestricted cash $10.29M, zero debt; Q4 legal expense expected for class action settlement but within guidance.

## SEC filing metadata
- accession: 0001683168-24-007620
- form_type: 8-K
- ticker: PAYS
- cik: 0001496443
- company_name: Paysign, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496443/000168316824007620/0001683168-24-007620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496443/000168316824007620/paysign_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-007620
- JSON: https://secwatch.observer/filing/0001683168-24-007620.json
- Plain text: https://secwatch.observer/filing/0001683168-24-007620.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.